Acral lentiginous melanoma

Acral lentiginous melanoma
Classification and external resources
Specialty oncology, dermatology
ICD-10 C43 (ILDS C43.L60)
ICD-9-CM 172.0-173.9
ICD-O M8744/3

Acral lentiginous melanoma is a kind of lentiginous[1] skin melanoma.[2][3] Melanoma is a potentially serious skin cancer that arises from pigment cells (melanocytes). Although acral lentiginous melanoma is rare in Caucasians and people with lighter skin types, it is the most common subtype in people with darker skins. Acral lentiginous melanoma is observed on the palms, soles, under the nails and in the oral mucosa. It occurs on non hair-bearing surfaces of the body, which may or may not be exposed to sunlight. It is also found on mucous membranes.[4] It is the most common form of melanoma diagnosed amongst Asian and Black ethnic groups.[5] The average age at diagnosis is between sixty and seventy years.[6]

Signs and symptoms

Typical signs of acral lentiginous melanoma include[7]

Warning signs are new areas of pigmentation, or existing pigmentation that shows change. If caught early, acral lentiginous melanoma has a similar cure rate as the other types of superficial spreading melanoma.[8]

Causes

Acral lentiginous melanoma is due as a result of malignant melanocytes. This occurs at the membrane of the skin (outer layers).[9]

Diagnosis

Even though the ideal method of diagnosis of melanoma should be complete excisional biopsy,[10] the location of the melanoma may require alternatives.Dermatoscopy of acral pigmented lesions is very difficult, but can be accomplished with diligent attention.Initial confirmation of the suspicion can be done with a small wedge biopsy or small punch biopsy.[11] Thin deep wedge biopsies can heal very well on acral skin, and small punch biopsies can give enough clue to the malignant nature of the lesion. Once this confirmatory biopsy is done a second complete excisional skin biopsy can be performed with a narrow surgical margin (1 mm). This second biopsy will determine the depth and invasiveness of the melanoma,[12] and will help to define what the final treatment will be. If the melanoma involves the nail fold and the nail bed, complete excision of the nail unit might be required.Final treatment might require wider excision (margins of 0.5 cm or more), digital amputation, lymphangiogram with lymph node dissection, or chemotherapy.[13]

Prognosis

Acral lentiginous melanoma (ALM)

It has been demonstrated that acral lentiginous melanoma has a poorer prognosis rate in comparison to cutaneous malignant melanoma (CMM).[14]

Histology

Histological signs of acral lentiginous melanoma include:[15]

According to Scolyer et al.,[16] ALM "is usually characterized in its earliest recognisable form as single atypical melanocytes scattered along the junctional epidermal layer".

Treatment

Therapies for metastatic melanoma include the biologic immunotherapy agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor trametinib.[17]

See also

References

  1. ↑ Phan A, Touzet S, Dalle S, Ronger-Savlé S, Balme B, Thomas L (August 2007). "Acral lentiginous melanoma: histopathological prognostic features of 121 cases". Br. J. Dermatol. 157 (2): 311–8. doi:10.1111/j.1365-2133.2007.08031.x. PMID 17596173.
  2. ↑ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
  3. ↑ "acral-lentiginous melanoma". Retrieved 2015-05-23.
  4. ↑ LeBoit, Philip E. (2006). Pathology and Genetics of Skin Tumours. IARC. ISBN 9789283224143.
  5. ↑ Farage, Miranda A. (2010-01-22). Textbook of Aging Skin. Springer Science & Business Media. ISBN 9783540896555.
  6. ↑ Swartz, Mark H. (2014-01-07). Textbook of Physical Diagnosis: History and Examination. Elsevier Health Sciences. ISBN 9780323225076.
  7. ↑ Goodheart, Herbert P. (2010-10-25). Goodheart's Same-site Differential Diagnosis: A Rapid Method of Diagnosing and Treating Common Skin Disorders. Lippincott Williams & Wilkins. ISBN 9781605477466.
  8. ↑ Hearing, Vincent J.; Leong, Stanley P. L. (2007-11-05). From Melanocytes to Melanoma: The Progression to Malignancy. Springer Science & Business Media. ISBN 9781592599943.
  9. ↑ Brown, Kimberly M.; Chao, Celia (2014). Melanoma. Elsevier Health Sciences. ISBN 9780323326834.
  10. ↑ Shea, Christopher R.; Reed, Jon A.; Prieto, Victor G. (2014-11-03). Pathology of Challenging Melanocytic Neoplasms: Diagnosis and Management. Springer. ISBN 9781493914449.
  11. ↑ ChB, David E. Elder MB; PhD, Sook Jung Yun MD (2014-11-10). Superficial Melanocytic Pathology. Demos Medical Publishing. ISBN 9781620700235.
  12. ↑ Barnhill, Raymond L.; Piepkorn, Michael; Busam, Klaus J. (2014-02-18). Pathology of Melanocytic Nevi and Melanoma. Springer Science & Business Media. ISBN 9783642383854.
  13. ↑ Clarke, Loren E.; Clarke, Jennie T.; Helm, Klaus F. (2014-03-01). Color Atlas of Differential Diagnosis in Dermatopathology. JP Medical Ltd. ISBN 9789350908457.
  14. ↑ Bradford, Porcia T.; Goldstein, Alisa M.; McMaster, Mary L.; Tucker, Margaret A. (2009). "Acral Lentiginous Melanoma: Incidence and Survival Patterns in the United States, 1986-2005". Archives of dermatology 145 (4): 427–434. doi:10.1001/archdermatol.2008.609. ISSN 0003-987X. PMC 2735055. PMID 19380664.
  15. ↑ Mooi, Walter; Krausz, Thomas (2007-09-28). Pathology of Melanocytic Disorders 2ed. CRC Press. ISBN 9781444113808.
  16. ↑ http://www.moloncol.org/article/S1574-7891(11)00029-9/fulltext#sec4.1.4
  17. ↑ Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F (2015). "Metastatic melanoma - a review of current and future treatment options". Acta Derm Venereol 95 (5): 516–524. doi:10.2340/00015555-2035. PMID 25520039.

Further reading

This article is issued from Wikipedia - version of the Sunday, April 10, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.